Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP; Annals of the Rheumatic Diseases (ARD Online) (Jan 2013)

Source: Ann Rheum Dis

Tags:

Arthritis

Psoriasis

secukinumab

Read more...

Psoriasis a Significant Risk Factor for Lower Rates of Pregnancy and Live Births

Presented at EADV

Source: DGNews  

Tags:

Pregnancy

Psoriasis

By Jenny Powers

Read more...

Perceptions of Expertise in Cutaneous Surgery and Cosmetic Procedures: What Primary Care Physicians Think

Ibrahimi OA, Bangash H, Green L, Alam M, Armstrong AW, Eisen DB; Dermatologic Surgery (Sep 2012)

Source: Dermatol Surg

Tags:

botulinum toxin

Read more...

NEMO gene rearrangement (exon 4-10 deletion) and genotype-phenotype relationship in Japanese patients with incontinentia pigmenti and review of published work in Japanese patients

Source: J Dermatol  

Okita M, Nakanishi G, Fujimoto N, Shiomi M, Yamada T, Wataya-Kaneda M, Takijiri C, Yokoyama Y, Sunohara A, Tanaka T; Journal of Dermatology (Feb 2013)

Tags:

Incontinentia pigmenti (IP) is a rare X-linked dominant genodermatosis caused by mutations of the NEMO gene, which is required for activation of the nuclear factor-κB signaling pathway. 

Read more...